GLUE vs. GPCR, CALT, TRVI, ELVN, TLRY, LENZ, NUVB, WVE, MAZE, and AMLX
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), Trevi Therapeutics (TRVI), Enliven Therapeutics (ELVN), Tilray Brands (TLRY), LENZ Therapeutics (LENZ), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), Maze Therapeutics (MAZE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs. Its Competitors
Structure Therapeutics (NASDAQ:GPCR) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Structure Therapeutics presently has a consensus price target of $75.71, suggesting a potential upside of 262.10%. Monte Rosa Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 218.78%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Monte Rosa Therapeutics.
Structure Therapeutics has a beta of -1.89, meaning that its stock price is 289% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.
91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Monte Rosa Therapeutics has a net margin of 13.58% compared to Structure Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Structure Therapeutics' return on equity.
In the previous week, Structure Therapeutics had 9 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 13 mentions for Structure Therapeutics and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.86 beat Structure Therapeutics' score of 1.28 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.
Monte Rosa Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 9/15/2025 by MarketBeat.com Staff
Free GLUE Stock Alerts